Loading...
OTCM
IPCIQ
Market cap0kUSD
Feb 21, Last price  
0.00USD
Name

Intellipharmaceutics International Inc

Chart & Performance

D1W1MN
P/E
P/S
0.00
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
-3.18%
Revenues
66k
0.00%
00000001,459,385501,814107,0911,527,4748,769,6934,093,7812,247,0025,504,4521,712,7311,401,5171,401,51765,72865,728
Net income
-3m
L-0.00%
0000000-5,761,091-4,880,277-6,136,865-11,495,017-3,856,353-7,436,388-10,143,577-8,937,533-13,738,888-3,390,965-5,145,155-2,892,394-2,892,394
CFO
-1m
L-0.00%
0000000-6,194,195-6,981,448-7,654,361-6,926,796-1,714,913-3,782,164-6,254,985-6,105,785-12,508,960112,108-2,461,329-1,388,223-1,388,223

Profile

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
IPO date
Jul 22, 1999
Employees
11
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑112021‑112020‑112019‑112019‑022017‑112016‑112015‑11
Income
Revenues
66
0.00%
Cost of revenue
2,149
Unusual Expense (Income)
NOPBT
(2,083)
NOPBT Margin
Operating Taxes
5
Tax Rate
NOPAT
(2,089)
Net income
(2,892)
0.00%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
2,326
Long-term debt
165
Deferred revenue
Other long-term liabilities
Net debt
2,408
Cash flow
Cash from operating activities
(1,388)
CAPEX
Cash from investing activities
500
Cash from financing activities
200
FCF
(5,882)
Balance
Cash
84
Long term investments
Excess cash
80
Stockholders' equity
(55,674)
Invested Capital
51,188
ROIC
ROCE
46.44%
EV
Common stock shares outstanding
33,093
Price
Market cap
EV
EBITDA
(1,877)
EV/EBITDA
Interest
292
Interest/NOPBT